TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01372046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Sessions
Description: Provides onsite booster sessions for one year to the group after participating in standard care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Sessions
Description: Provides onsite booster sessions for one year to the group after participating in standard care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: memorandums, staff meetings
Study: NCT03918057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia
Description: Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
Study: NCT00678418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL® 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
Study: NCT02936375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: 25mg twice a day, orally administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1g/m², every 4 weeks, intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 2mg/kg·d, once a day, orally administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
Study: NCT05504317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive corresponding dose of placebo injection subcutaneously.
Study: NCT02427945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information on safe water
Description: A promoter from Evidence Action will visit the household and provide information on safe water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information on safe water and child nutrition
Description: A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information on safe water and child nutrition
Description: A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
Study: NCT02006524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'MyDiagnostick
Study: NCT01223352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
Study: NCT03162198

Intervention type: OTHER
Intervention: Cirrhosis with HCC
Description: Cirrhosis with Hepatocellular Carcinoma

Intervention type: OTHER
Intervention: Cirrhosis without HCC
Description: Cirrhosis without Hepatocellular Carcinoma
Study: NCT05595252

Intervention type: BIOLOGICAL
Intervention: cervical biopsy
Description: cervical biopsy made during and after pregancy
Study: NCT02881346

Intervention type: DRUG
Intervention: Enstilar®
Description: Once daily application of cutaneous foam to plaques on body and/or extremities
Study: NCT04094441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: chest physiotherapy
Study: NCT03083418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control group
Description: No EDP treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDP
Description: Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
Study: NCT00570271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP dec (written form)
Description: Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP dec (doctor)
Description: Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP inc (written)
Description: Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
Study: NCT03775928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 425mg qd po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 1000mg/m2 bid d1-d14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine 1000mg/m2 bid d1-d14
Study: NCT03030859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Undergo usual care only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care plus LEF-SCP
Description: Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care plus LEF-SCP plus Follow-up
Description: Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
Study: NCT04276415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6157a
Description: Administered as a single agent intravenously (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6157a
Description: Administered as a single agent intravenously (IV) every 3 weeks
Study: NCT00570271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP inc (doctor)
Description: Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Placebo info given (written)
Description: Subject informed about receiving placebo. Information provided to subjects in written form.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Placebo info given (doc)
Description: Subject informed about receiving placebo. Information provided to subjects by doctor.
Study: NCT04196465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-001
Description: IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys
Study: NCT04281680

Intervention type: DRUG
Intervention: Pasireotide 0.9 MG/ML
Description: 900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
Study: NCT04725149

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 500 ml base solution
Description: Color, taste, aroma, and calorie matched water base

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500 ml containing 30 ml tart cherry concentrate diluted with water and base solution
Description: Montmorency cherry concentrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500 ml containing 60 ml tart cherry concentrate diluted with water only
Description: Montmorency cherry concentrate
Study: NCT02704351

Intervention type: PROCEDURE
Intervention: Surgery
Description: Sugammadex to reverse neuromuscular blockade
Study: NCT00764309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg, once daily, 6 months
Study: NCT04578743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy: ClearPlay(TM)
Description: ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy: ClearPlay(TM)
Description: ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
Study: NCT03378700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention
Description: The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-dialysis Education Group
Description: Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
Study: NCT02419352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/atropine
Study: NCT00765700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Ketoprofen 10% Cream
Description: Topical Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Cream
Description: Topical Administration
Study: NCT00584766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Description: Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
Study: NCT02473809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT04276415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6157a
Description: Administered as a single agent intravenously (IV) every 3 weeks
Study: NCT02936375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
Study: NCT01106131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg
Description: Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
Study: NCT03655886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical prostatectomy
Description: can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole pelvis radiotherapy
Description: radiation of prostate bed and pelvis
Study: NCT01118013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT00661089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A - OnabotulinumtoxinA
Description: 100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
Study: NCT01118013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study: NCT00661089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Saline)
Description: Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
Study: NCT01118013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduced-intensity transplant conditioning procedure
Study: NCT01305564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denali inferior vena cava filter
Description: The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
Study: NCT01088971

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Duolac7S
Description: 1 capsule two times everyday for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: 1capsule two times everyday for 6 weeks
Study: NCT01187732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Washing without water
Description: The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Washing without water
Description: The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
Study: NCT00274742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab (MT103)
Description: Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
Study: NCT02786992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study: NCT01118013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01142115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent catheter CP063CC
Description: intermittent catheterisation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheter CP063CC
Description: intermittent catheterisation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath
Description: intermittent catheterisation
Study: NCT02773004

Intervention type: OTHER
Group type: OTHER
Intervention: EPClin genomic test
Study: NCT00599443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal cell-derived influenza vaccine
Description: 0.5 mL im, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 0.5 mL im, single dose
Study: NCT03321877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Change to dose of patient's regular medication
Description: Dose reduction of the drug each patient was already taking
Study: NCT04445987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-154
Description: ARQ-154 foam 0.3% applied once daily for 52 weeks
Study: NCT02091206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 5 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 10 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Study: NCT01141153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid + clopidogrel + acenocoumarol
Description: Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid + clopidogrel
Description: Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent.
Study: NCT02458222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: language game therapy
Description: participants will take part in game therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: language game therapy
Description: participants will take part in game therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: usual clinical care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: usual clinical care
Study: NCT02341443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants
Description: Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implants
Description: Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate.
Study: NCT00329810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, oral, 15 mg, once daily, 12 weeks.
Study: NCT01869023

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles